Independent Specialty Pharmacy Achieves URAC Small Business Accreditation in Six Months
Last updated: April 2026
An independent specialty pharmacy serving patients with complex chronic conditions engaged IHS to navigate URAC's Small Business Specialty Pharmacy Accreditation program. Starting from a compliance posture typical of independent pharmacies — strong clinical operations, limited formal documentation infrastructure — the pharmacy achieved URAC accreditation within six months of initial engagement, corrected six deficiency categories before application submission, and secured the payer network access that had been unavailable without the credential. This case study describes the engagement structure, the deficiencies identified and corrected, and the market outcome.
Client identity is withheld per IHS confidentiality standards. Organizational details have been generalized to protect client information.
The Client
A privately held independent specialty pharmacy with a single dispensing location, operating in a competitive regional market where two PBM-affiliated specialty chains held the dominant market share. The pharmacy had been in operation for approximately two years, dispensing specialty medications across several therapeutic categories including oncology support, immunology, and rare disease.
The pharmacy's clinical team was experienced and patient outcomes were strong. Patient satisfaction indicators were high. The pharmacists-in-charge had substantial specialty pharmacy experience from prior employment at larger organizations. What the pharmacy lacked was not clinical capability — it was the documented, structured compliance infrastructure that URAC's nine-module standards framework requires.
The Business Problem
The pharmacy had been excluded from two regional PBM specialty pharmacy networks because it did not hold URAC accreditation. The network exclusion was not a judgment about the pharmacy's clinical quality — it was an automatic filtering criterion. The PBMs required URAC, ACHC, or TJC accreditation as a condition of specialty network application review. Without accreditation, the application was not evaluated on its merits.
The excluded networks covered a substantial portion of the commercially insured patient population in the pharmacy's geographic market. Patients with those plan coverages could not use the pharmacy for specialty drugs — even patients who specifically requested it. The pharmacy was losing referrals from prescriber offices because the prescribers' preferred specialty pharmacy had to be in-network for the patient's plan.
The pharmacy's principals had researched accreditation independently and concluded that the process was achievable but that the documentation requirements across nine standards modules exceeded what their internal team could build without expert guidance on the correct standards interpretation. They engaged IHS after reviewing the firm's URAC background, specifically the principal's prior role as Chief Operating Officer and General Counsel of URAC.
The IHS Engagement
Phase 1: Gap Assessment (Weeks 1–4)
IHS began with a structured standard-by-standard review across all nine URAC modules. The gap assessment was conducted through document review, operational interviews with the pharmacy's pharmacists-in-charge and operations manager, and direct observation of workflow documentation practices.
The assessment produced a written gap report covering every module. The findings fell into two categories: modules where the pharmacy had the underlying operational compliance but lacked documentation structure to demonstrate it to URAC reviewers; and modules where actual operational infrastructure was missing and needed to be built before any documentation could be written.
The distribution of findings was consistent with IHS's experience across independent pharmacy accreditation engagements:
- Documentation gaps (present operation, absent documentation): Patient Management (PM), Patient Service and Communication (P-PSC), Pharmacy Operations (P-OPS)
- Infrastructure gaps (absent operation): Risk Management (RM), Performance Monitoring and Improvement (PMI), Reporting Performance Measures (RPT)
- Moderate gaps (partial operation and partial documentation): Operations and Infrastructure (OPIN), Medication Distribution (P-MD), Consumer Protection and Empowerment (CPE)
The most significant finding in the gap assessment was the Risk Management module. The pharmacy had no formal risk management program — no written risk management plan, no designated risk oversight function, no documented risk identification or mitigation activities. This was not unusual; few independent pharmacies operate with formal risk management infrastructure before pursuing accreditation. But the RM module is fully scored at committee review, and building compliant RM infrastructure takes time — it cannot be drafted the week before submission. The gap assessment's identification of this in week two gave the pharmacy twelve weeks to build it before the evidence record needed to be complete.
Phase 2: Documentation and Infrastructure Development (Weeks 4–16)
IHS provided templates for all required documentation across the nine modules. The pharmacy's internal team adapted the templates to their specific operations, with IHS reviewing drafts for standards alignment and flagging language or structural gaps before finalization.
The documentation work proceeded module by module, sequenced by the remediation priority established in the gap report. Risk Management infrastructure was built first given its lead time requirements. Quality measure data collection systems were installed in week five — not because the data was needed for the application immediately, but because the RPT module required evidence of ongoing collection, and that evidence had to accumulate over the accreditation preparation period.
Key documentation produced during this phase:
- Risk Management: Written risk management plan, designated risk oversight governance, documented risk register with identification and mitigation activities, risk monitoring schedule
- OPIN: Personnel credentialing files for all pharmacists and technicians restructured to URAC format with primary source verification documentation, staff training records, governance documentation
- PMI and RPT: Quality measure selection and data collection protocols, measurement calendar, performance reporting templates, baseline data collection initiated
- CPE: Patient rights documentation updated to URAC CPE standards, grievance and appeal procedure formalized and documented, consumer information materials reviewed against CPE requirements
- PM: Patient management documentation protocols established — therapy initiation assessments, ongoing monitoring records, adverse event tracking logs, prescriber coordination documentation
- P-MD: Cold-chain and temperature excursion management protocols written to URAC specificity, delivery confirmation documentation system installed
- P-OPS: Existing pharmacy operations policies reviewed, reorganized to URAC module alignment, gaps filled
- P-PSC: Patient outreach logs, medication counseling documentation, adherence support records formalized
Phase 3: Mock Review (Weeks 16–20)
IHS conducted a structured mock review simulating the URAC desktop review process. The mock review audited the pharmacy's complete documentation record against the nine-module standards, testing the completeness and internal consistency of the evidence package that would be submitted to URAC.
The mock review identified three remaining gaps that had not been fully closed during the documentation phase:
- PM module: Patient management records for a subset of complex therapy patients lacked the prescriber coordination documentation required by the standard. The underlying coordination activity had occurred — it was not being systematically recorded in the patient file. IHS provided a corrective documentation protocol; the pharmacy completed remediation within one week.
- OPIN module: Two staff members had certifications that were current but not verified from primary source. The certificates on file were copies, not primary source verification records. IHS directed the pharmacy to obtain primary source verification letters directly from the certifying bodies. Completed within ten days.
- CPE module: The pharmacy's grievance log did not capture resolution timelines in a format that demonstrated compliance with the required response window. The log format was revised to include intake date, response date, and calculated resolution timeline. Existing entries were updated with available data.
No gaps were identified in the Risk Management, PMI, RPT, P-MD, P-OPS, or P-PSC modules. The documentation infrastructure built during Phase 2 held up under mock review scrutiny in those areas.
Phase 4: Application Submission and Committee Review (Weeks 20–26)
IHS supported the formal application submission — packaging the complete evidence record, coordinating with URAC during the application agreement process, and preparing the pharmacy's principals for the accreditation committee review process.
URAC issued one Request for Information (RFI) during the desktop review phase, seeking additional clarification on the pharmacy's quality measure data collection methodology under the RPT module. IHS drafted the RFI response within 48 hours of receipt, providing a detailed description of the data collection system and supplementary documentation demonstrating ongoing collection since week five of the engagement. URAC accepted the response without further inquiry.
The accreditation committee review resulted in approval. URAC Specialty Pharmacy Accreditation was issued in month six of the IHS engagement — within URAC's stated six-months-or-less timeline.
Deficiency Categories and How Each Was Resolved
The six deficiency categories identified in the gap assessment represent the failure patterns IHS most commonly encounters in independent pharmacy accreditation engagements. Each is detailed below with the specific finding and the resolution approach.
1. Risk Management Infrastructure (RM Module) — Infrastructure Gap
Finding: No formal risk management program in place. The pharmacy had informal awareness of operational risks but no written program, no governance structure for risk oversight, and no documented risk identification or mitigation activities.
Resolution: IHS provided a risk management program framework template. The pharmacy's pharmacist-in-charge and operations manager built the program over six weeks — designating risk oversight governance, completing an initial risk identification exercise, documenting mitigation activities for identified risks, and establishing a monitoring schedule. By week ten, the pharmacy had a functioning, documented risk management program with three months of evidence before the application was submitted.
Common mistake avoided: Many pharmacies draft a risk management policy without building the underlying program. A document that says "we will identify and mitigate risks" without evidence of the identification and mitigation activities does not satisfy the RM module. URAC reviewers look for the activity record, not just the policy statement.
2. Quality Measure Data Collection (PMI and RPT Modules) — Infrastructure Gap
Finding: No structured quality measure collection system in place. The pharmacy tracked some operational metrics informally, but not in a format that could be submitted as evidence of standards-compliant quality measurement and reporting.
Resolution: IHS identified the specific measures the pharmacy was required to collect and report under the RPT module and designed a data collection protocol that could be operated by the pharmacy's existing staff without dedicated data management resources. The collection system was installed in week five. By the time of application submission in week twenty, the pharmacy had fifteen weeks of quality measure data — sufficient to demonstrate ongoing collection and emerging performance trends.
Common mistake avoided: Quality measure data cannot be reconstructed retroactively. Pharmacies that attempt to collect historical data from billing records, patient files, or operational logs after the fact produce evidence that URAC reviewers treat skeptically. Data collection must start before the accreditation preparation clock starts — which means it must start before many pharmacies think it needs to start.
3. Patient Management Documentation (PM Module) — Documentation Gap
Finding: Clinical patient management activities were occurring — pharmacists were conducting therapy initiation assessments, monitoring patients on complex specialty therapies, tracking adverse events, and coordinating with prescribers. None of it was being systematically documented in a retrievable patient record format aligned with URAC's PM module requirements.
Resolution: IHS provided patient management documentation templates — therapy initiation assessment forms, ongoing monitoring record formats, adverse event tracking logs, and prescriber coordination record templates. The pharmacy implemented the templates in week six. Patient files were prospectively documented from that point forward. Existing patients were retrospectively documented to the extent that contemporaneous records permitted.
Common mistake avoided: Independent pharmacy pharmacists typically have more clinical engagement with specialty patients than their counterparts at PBM-affiliated chains. That clinical engagement is a competitive strength — but it only translates to accreditation credit when it is documented. Undocumented clinical activity does not exist in a URAC desktop review.
4. Consumer Protection Procedures (CPE Module) — Moderate Gap
Finding: The pharmacy had patient rights documentation and a basic grievance process, but both were written to state pharmacy board standards rather than URAC's CPE module requirements. The grievance log did not capture resolution timelines. Consumer information materials lacked several elements required by the CPE standard.
Resolution: IHS reviewed all CPE documentation against the module requirements element by element. Patient rights documentation was updated. The grievance procedure was revised to include required elements and a log format that captured intake date, response date, and resolution timeline. Consumer information materials were revised to include required URAC CPE content. All revisions were completed by week eight.
Common mistake avoided: State pharmacy board compliance and URAC CPE compliance are not the same. The CPE module requires specific content, format, and process elements that go beyond typical state disclosure requirements. Pharmacies that assume their existing patient-facing materials satisfy CPE without reviewing them against the actual standard consistently find gaps.
5. Personnel Credentialing Documentation (OPIN Module) — Moderate Gap
Finding: All pharmacy personnel held current licenses and certifications. The documentation on file was copies of certificates and license printouts — not primary source verification records. URAC's OPIN module requires primary source verification of credentials, not possession of copies.
Resolution: IHS directed the pharmacy to obtain primary source verification letters directly from the licensing boards and certifying bodies for all pharmacy staff. The verification letters were obtained over a ten-day period. Personnel files were restructured to URAC format — primary source verification letters filed with license and certification copies, with a verification date tracking log for each staff member.
Common mistake avoided: The distinction between possessing a copy of a credential and having primary source verification of a credential is a standard distinction across multiple accreditation programs. Independent pharmacies consistently underestimate how specific URAC's OPIN documentation requirements are relative to standard pharmacy employer practices.
6. Medication Distribution Protocols (P-MD Module) — Moderate Gap
Finding: The pharmacy dispensed specialty biologics and injectables requiring cold-chain management. The pharmacy had cold-chain procedures in practice but not written to URAC's P-MD specificity — temperature excursion management documentation was informal, and delivery confirmation records did not capture all elements required by the standard.
Resolution: IHS provided cold-chain management and temperature excursion protocol templates aligned with URAC P-MD requirements. The pharmacy's existing procedures were documented formally. The delivery confirmation record format was revised to capture required elements. Training documentation for staff on the updated protocols was completed and filed. Revisions were complete by week ten.
Common mistake avoided: URAC's P-MD module requirements for cold-chain documentation are more specific than USP <797> and state pharmacy board requirements for temperature monitoring. Pharmacies that assume their existing cold-chain procedures satisfy P-MD without reviewing them against the actual standard find gaps in documentation specificity, not in operational practice.
Outcomes
Accreditation Achievement
URAC Specialty Pharmacy Accreditation was issued in month six of the IHS engagement. The application produced one RFI — on the RPT module quality measure data collection methodology — which was resolved with a single IHS-drafted response. No other deficiencies were cited at the committee review stage. All six deficiency categories identified in the gap assessment were corrected before application submission.
Payer Network Access
Following credential issuance, the pharmacy submitted applications to the two regional PBM specialty pharmacy networks from which it had previously been excluded. Both networks reviewed the applications and credentialed the pharmacy for specialty network participation. The pharmacy gained access to the commercially insured patient population those networks covered — the market segment that had been structurally unavailable before accreditation.
Competitive Position
With URAC accreditation in hand, the pharmacy's clinical advantages — higher-touch patient management, faster prior authorization support, more responsive pharmacist-prescriber coordination — became convertible into market position. The accreditation credential provided the baseline quality signal that payers and prescribers require before they evaluate the clinical differentiation independent pharmacies actually provide.
The pharmacy's principals noted that prescriber offices that had previously been reluctant to refer specialty patients — because out-of-network status created friction — began directing referrals to the pharmacy following network credentialing. The accreditation credential was the prerequisite that made the pharmacy's clinical reputation commercially actionable.
Mid-Cycle Position
The quality measure collection infrastructure installed during the accreditation engagement gave the pharmacy an ongoing performance monitoring capability that extended beyond accreditation compliance. The pharmacy's quality committee began using the measure data for operational improvement decisions — identifying adherence support gaps, therapy discontinuation patterns, and patient communication touchpoints where intervention improved outcomes. The accreditation infrastructure became operational infrastructure.
Lessons for Independent Specialty Pharmacies
This engagement illustrates three patterns that IHS observes consistently across independent pharmacy accreditation engagements.
The Gap Is Not Clinical — It Is Structural
Independent specialty pharmacies typically have strong clinical operations. The pharmacists are experienced, the patient relationships are close, and the clinical outcomes are competitive with larger chain organizations. What they lack is not clinical capability — it is the documented, structured compliance infrastructure that URAC's nine-module framework requires. The gap assessment phase exists to distinguish between the two: what needs documentation versus what needs to be built.
Time Is the Constraining Resource, Not Effort
The Risk Management and quality measure gaps in this engagement required twelve and fifteen weeks of lead time, respectively — not because building them is difficult, but because URAC reviewers require evidence of ongoing operation over time, not documentation produced the week before submission. Gap assessment must happen early enough that infrastructure gaps can be built with sufficient evidence lead time. A pharmacy that begins the accreditation process six weeks before it wants to submit is not behind on work — it is behind on time.
Mock Review Catches What Self-Review Misses
The three gaps identified during the Phase 3 mock review — PM module prescriber coordination records, OPIN primary source verification for two staff members, and CPE grievance log format — were not caught by the pharmacy's internal review of their own documentation. All three were operational realities that the pharmacy's team had reviewed and considered complete. The mock review's external perspective, structured around how URAC reviewers actually audit documentation, identified the gaps before they became RFIs. An RFI on each of those three findings would have extended the timeline and required remediation under time pressure. The mock review converted them from post-submission problems into pre-submission corrections.
Related Resources
Is Your Pharmacy Facing the Same Network Access Problem?
Schedule a no-obligation consultation with IHS. We will assess your current compliance posture, identify which deficiency categories apply to your organization, and give you a clear timeline and engagement structure for URAC Specialty Pharmacy Small Business Accreditation.